HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

This article was originally published in The Rose Sheet

Executive Summary

The Estee Lauder Companies-backed startup has been highly successful despite erratic and, in the eyes of many, concerning behavior from founder Brandon Truaxe. In his latest – and supposedly last – Instagram post for the brand, Truaxe says DECIEM will be shutting down operations and renews claims about corruption within the organization.

You may also be interested in...



DECIEM Analyzes Billions Of Google Searches To Tackle Cosmetic Ingredient ‘Misconceptions’

The Estee Lauder Companies’ outfit breaks down the cosmetic safety assessment process, the science of skin inflammation and sensitivity, and safe and effective use of highly searched ingredients including zinc, hyaluronic acid and retinol in a September report aimed at bringing clarity to conversations online.

Estee Lauder Companies To Make ‘Abnormal Beauty’ Its Own

The beauty titan will increase its stake in DECIEM to 76% in a deal valuating The Ordinary skin-care owner at $2.2bn. Remaining interests will be acquired after three years, according to the announcement.

Health, Beauty And Wellness News: FDA Shutdown, Kemin Marketing VP, More

FDA cosmetics operations likely shuttered with shutdown; Stomp leads Kemin's global marketing; Unilever delivers on fragrance transparency pledge; Lentein protein to Canada through CK Ingredients; and Deciem founder Truaxe dead at 40.

Related Content

Topics

UsernamePublicRestriction

Register

RS121866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel